EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases

David A Schoenfeld iD, Myrto Moutafi iD, Sandra Martinez, Dijana Djureinovic, Ross D Merkin, Adebowale Adeniran, David A Braun iD, Sabina Signoretti, Toni K Choueiri iD, Fabio Parisi, Michael Hurwitz, David L Rimm iD und 3 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-007240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von David A Schoenfeld und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Brain Neoplasms, Immune System Diseases, Kidney Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The tumor microenvironment (TME) contributes to cancer progression and treatment response to therapy, including in renal cell carcinoma (RCC). Prior profiling studies, including single-cell transcriptomics, often involve limited sample sizes and lack spatial orientation. The TME of RCC brain metastases, a major cause of morbidity, also remains largely uncharacterized.

Methods

We performed digital spatial profiling on the NanoString GeoMx platform using 52 validated immuno-oncology markers on RCC tissue microarrays representing progressive stages of RCC, including brain metastases. We profiled 76 primary tumors, 27 adjacent histologically normal kidney samples, and 86 metastases, including 24 brain metastases.

Results

We observed lower immune checkpoint (TIM-3 and CTLA-4), cytolytic (GZMA and GZMB), and T cell activation (CD25) protein expression in metastases compared with primary tumors in two separate cohorts. We also identified changes in macrophages in metastases, with brain metastases-susceptible patients showing less M1-like, inflammatory macrophage markers (HLA-DR and CD127) in metastatic samples. A comparison of brain metastases to extracranial metastases revealed higher expression of the anti-apoptotic, BCL-2-family protein BCL-XL and lower expression of the innate immune activator STING in brain metastases. Lower TIM-3 and CD40 in the TME of brain metastases appear to be associated with longer survival, a finding that requires further validation.

Conclusions

Compared with primary tumors, RCC metastases, including brain metastases, express lower levels of numerous markers of immune activation and current or investigational therapeutic targets. Our findings may have important implications for designing future biomarker and treatment studies and may aid in development of brain metastases-specific therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellBrain NeoplasmsImmune System DiseasesKidney NeoplasmsHumansHepatitis A Virus Cellular Receptor 2Medical OncologyTumor Microenvironment

Stichwörter der Autor:innen

Biomarkers, TumorBrain NeoplasmsImmunotherapyRenal Cell CarcinomaTumor Microenvironment

Substanzen

Hepatitis A Virus Cellular Receptor 2

Autor:innen und Institutionen

  • School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA.
  • School of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA Harriet.Kluger@Yale.edu.

ORCID-Profile: David A Schoenfeld, Myrto Moutafi, David A Braun, Toni K Choueiri, David L Rimm, Harriet M Kluger

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NIH

Zitieren

APA

Schoenfeld, D. A., Moutafi, M., Martinez, S., Djureinovic, D., Merkin, R. D., Adeniran, A., Braun, D. A., Signoretti, S., Choueiri, T. K., Parisi, F., Hurwitz, M., Rimm, D. L., Wei, W., Jilaveanu, L., & Kluger, H. M. (2023). Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007240

Vancouver

Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, et al. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-007240

BibTeX
@article{Schoenfeld2023,
  author = {Schoenfeld, David A and Moutafi, Myrto and Martinez, Sandra and Djureinovic, Dijana and Merkin, Ross D and Adeniran, Adebowale and Braun, David A and Signoretti, Sabina and Choueiri, Toni K and Parisi, Fabio and Hurwitz, Michael and Rimm, David L and Wei, Wei and Jilaveanu, Lucia and Kluger, Harriet M},
  title = {Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-007240}
}
Kostenlos starten →